Salivary Gland Neoplasms
Information
- Disease name
- Salivary Gland Neoplasms
- Disease ID
- Description
Disease area statistics
Chromosome band
| Gene symbol | Chromosome | Start | Stop | The number of variant |
|---|---|---|---|---|
| TP53 | 17 | 7,668,421 | 7,687,490 | 74 |
| BRAF | 7 | 140,719,337 | 140,924,929 | 46 |
| EWSR1 | 22 | 29,268,316 | 29,300,343 | 42 |
| ROS1 | 6 | 117,288,300 | 117,425,855 | 40 |
| ERBB2 | 17 | 39,700,064 | 39,728,658 | 36 |
| NF1 | 17 | 31,094,977 | 31,377,675 | 30 |
| PIK3CA | 3 | 179,148,357 | 179,240,093 | 28 |
| ZFHX3 | 16 | 72,782,885 | 73,891,871 | 22 |
| ETV6 | 12 | 11,649,674 | 11,895,377 | 20 |
| FGFR2 | 10 | 121,478,332 | 121,598,444 | 18 |
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04325828 | Active, not recruiting | Phase 2 | A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma | April 7, 2020 | September 30, 2025 |
| NCT03602079 | Completed | Phase 1/Phase 2 | Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene | July 16, 2018 | January 12, 2022 |
| NCT00568438 | Completed | Immunohistochemical & Immunoblot Analysis of NIS (Na+/I-Symporter) in Archival & Frozen Tissue Sample | October 2000 | December 31, 2015 | |
| NCT05390294 | Completed | Survival With Patients Treated With Salivary Gland Cancer | January 1, 2022 | April 30, 2022 | |
| NCT03942380 | Recruiting | N/A | Cell-free Tumor DNA in Head and Neck Cancer Patients | February 1, 2017 | February 1, 2025 |
| NCT04644315 | Terminated | Phase 2 | A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors | May 24, 2021 | May 16, 2022 |
| NCT05087706 | Unknown status | Exploratory Study of Molecular Profile-Associated Evidence Guided Precision Therapy for Salivary Gland Cancer（MAPS） | July 30, 2021 | September 19, 2023 | |
| NCT04832438 | Withdrawn | Phase 2 | 9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma | December 18, 2030 | June 18, 2034 |
- MeSH unique ID (MeSH (Medical Subject Headings))
- D012468